Medidata and Novotech extend partnership to scale clinical research
Category: #health  By Pankaj Singh  Date: 2022-06-17
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Medidata and Novotech extend partnership to scale clinical research

Dassault Systèmes subsidiary Medidata and leading CRO (contract research organization) Novotech have expanded their partnership to continue advancements in clinical research across different therapeutic areas.

Leveraging Medidata’s Rave RTSM, Rave EDC, eConsent, and eCOA technology, Novotech is fitted with configurable, flexible tools that can acknowledge clinical research requirements and ease fast-track device and drug development in the U.S. and the Asia Pacific.

Since its collaboration in 2018, Novotech has acquired CRO firms in the United States as well as APAC, and has doubled its growth. It has also invested in data and advanced DCT companies to provide a flawless CRO platform amid the growing demand for clinical trial services across the region.

The collaboration expands access to a portfolio of comprehensive solutions from Medidata Clinical Cloud, the only consolidated platform in the industry dedicated to clinical research.

Furthermore, it accentuates Novotech and Medidata’s commitment to work together toward effective acceleration of clinical research and trials while enhancing patient experiences and clinical trial timelines.

The solutions offered by the Medidata Clinical Cloud use centralized data to address the overall research process. Digital integration is crucial for expedited clinical development since the COVID-19 pandemic imposed physical limitations and fragmented healthcare ecosystems.

A combined platform enables optimized management of sites, users, studies, and access from one location.

Edwin Ng, APAC Senior Vice President at Medidata has expressed that the pandemic emphasized the importance of redesigning trial operations, with more shareholders understanding the significance of the technology in clinical development.

Furthermore, Novotech’s Senior Director Biometrics Andries Claassen has noted that Medidata’s sustained support in steering business growth and clinical research allowed the company to continue its partnership with the company.

Medidata creates hope for many patients by pioneering the digital transformation of life sciences. It helps in generating the insights and evidence to help biotech, pharmaceutical, diagnostics, and medical device companies expedite value, optimize outcomes, and mitigate risk.

Source credit:

https://www.prnewswire.com/in/news-releases/novotech-and-medidata-expand-partnership-to-continue-advancements-in-clinical-research-841550990.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

By Pankaj Singh

Rona Therapeutics Inc has reportedly acquired the global exclusive rights to the siRNA platform of delivery moiety and chemical modification from Sanofi S.A., in addition to four pre-clinical contenders for unrevealed ...

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

By Pankaj Singh

California-based toy manufacturing and entertainment company, Mattel, has recently signed a multi-year agreement with Elon Musk’s private spaceflight company, SpaceX.

T...

USHV partners with Willowbrook to provide quality cardiovascular care

USHV partners with Willowbrook to provide quality cardiovascular care

By Pankaj Singh

US Heart & Vascular (USHV) is reportedly partnering with Willowbrook Cardiovascular Associates to offer quality cardiovascular care in the Houston market.

USHV has a strong ma...